Respiratory Research (Sep 2024)

CXCL10 predicts autoimmune features and a favorable clinical course in patients with IIP: post hoc analysis of a prospective and multicenter cohort study

  • Noriyuki Enomoto,
  • Shogo Nakai,
  • Shusuke Yazawa,
  • Yasutaka Mochizuka,
  • Atsuki Fukada,
  • Yuko Tanaka,
  • Hyogo Naoi,
  • Yusuke Inoue,
  • Hideki Yasui,
  • Masato Karayama,
  • Yuzo Suzuki,
  • Hironao Hozumi,
  • Kazuki Furuhashi,
  • Mikio Toyoshima,
  • Masato Kono,
  • Shiro Imokawa,
  • Masato Fujii,
  • Taisuke Akamatsu,
  • Naoki Koshimizu,
  • Koshi Yokomura,
  • Hiroyuki Matsuda,
  • Yusuke Kaida,
  • Yutaro Nakamura,
  • Masahiro Shirai,
  • Kazutaka Mori,
  • Masafumi Masuda,
  • Tomoyuki Fujisawa,
  • Naoki Inui,
  • Hiroaki Sugiura,
  • Hiromitsu Sumikawa,
  • Masashi Kitani,
  • Kazuhiro Tabata,
  • Noriyoshi Ogawa,
  • Takafumi Suda

DOI
https://doi.org/10.1186/s12931-024-02982-0
Journal volume & issue
Vol. 25, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Background Interstitial pneumonia with autoimmune features (IPAF), which does not meet any of the criteria for connective tissue diseases (CTD), has been attracting an attention in patients with idiopathic interstitial pneumonia (IIP). However, the biomarkers that reflect the clinical course of these patients have not been fully elucidated. Objective To identify useful serum biomarkers reflecting CTD-related features and favorable prognoses in patients with IIP. Methods This was a post hoc analysis of a prospective and multicenter cohort study between 2015 and 2020. Newly diagnosed patients with IIP were consecutively enrolled, and 74 autoimmune features and autoantibodies were comprehensively checked during IIP diagnosis. Serum levels of CXCL10, CXCL1, CCL2, BAFF, angiopoietin-2, and leptin were evaluated at the time of IIP diagnosis. Results Two hundred twenty-two patients (159 men and 63 women) with IIP were enrolled. The median observation duration was 36 months. The median age was 71 years old, and median %forced vital capacity (FVC) was 84.1% at the time of IIP diagnosis. The proportion of patients who met the classification criteria for IPAF was 11.7%. In patients with high serum CXCL10, changes in both %FVC and %diffusion lung capacity for carbon monoxide at one year were significantly higher than those in patients with low CXCL10 (p = 0.014 and p = 0.009, respectively), whereas these changes were not significant for other chemokines and cytokines. High CXCL10 levels were associated with acute/subacute onset (p < 0.001) and the diagnosis of nonspecific interstitial pneumonia with organizing pneumonia overlap (p = 0.003). High CXCL10 levels were related to a higher classification of IPAF (relative risk for IPAF was 3.320, 95%CI: 1.571–7.019, p = 0.003) and lower classification of progressive pulmonary fibrosis (PPF; relative risk for PPF was 0.309, 95%CI: 0.100-0.953, p = 0.027) compared to those with low CXCL10. Finally, survival was higher in patients with IPF and high CXCL10 (p = 0.044), and high CXCL10 was a significant prognostic factor in multivariate Cox proportional hazards models (hazard ratio 0.368, p = 0.005). Conclusions High serum levels of CXCL10 are associated with CTD-related features, the favorable clinical course, and survival in patients with IIP, especially IPF. Clinical trial number Not applicable.

Keywords